- No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
CHRS
NASDAQ
Week ended 31 Jul 2026
Weekly Investor Report
Coherus BioSciences Inc · Healthcare · Biotechnology
Latest close
1.41 USD
0.0%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is -14.8% below the Trend Line and sits at 33.2% of its 52-week range. The latest completed week returned 0.0%, after a -2.8% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is expensive relative to peers. Options positioning is volatility with 51/100 conviction, while the latest news-sentiment score is 50/100. Near-term considerations: volume confirmation is below normal; earnings are due in 3d.
Setup score
23
out of 100
Latest Close
1.41 USD
31 Jul 2026
1W Return
0.0%
latest completed week
4W Return
-2.8%
short-term follow-through
12W Return
-19.4%
quarterly tape
Trend Breadth
75.0%
39 of 52 weeks active
Volume Ratio
0.5x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
0.0%
Latest completed week; four-week move -2.8%.
Indicator stack
41/28
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 40.94%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
Options pressure
Volatility
51/100 conviction; expected move 18.1%.
News sentiment
50/100
71 relevant articles in the latest sentiment read.
Event risk
3d
Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -14.8% below the Trend Line and sits at 33.2% of its 52-week range. The latest completed week returned 0.0%, after a -2.8% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.5x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.1012-week average 0.30
12-week confirmation
Trend active3/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.10Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -2.8% over four weeks, -19.4% over 12 weeks, and 60.6% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year39
Trend breadth75.0%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-1.19Latest activity-pressure read.
Pressure change-8.4%Four-week change in activity pressure.
Leadership-15.68Latest relative-leadership reading.
RS change-3.3%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is expensive relative to peers.
Factor week 26 Jul 2026
Financial statements through 31 Mar 2026
Field coverage 82%
Model confidence 78%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength16/100Blend of value, momentum, and quality. Underlying universe rank 85; rank 1 is best.
Value21/100Relative valuation strength. Underlying universe rank 80; rank 1 is best.
Quality9/100Profitability and accounting quality. Underlying universe rank 92; rank 1 is best.
Momentum81/100Medium-term price momentum. Underlying universe rank 20; rank 1 is best.
Growth11/100Revenue and earnings growth. Underlying universe rank 90; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 4.6x Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -108.9% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 60.0% Gross profit retained from each unit of revenue.
- Operating margin
- -349.0% Operating profit retained from revenue.
- Free-cash-flow margin
- -363.8% Free cash flow generated from revenue.
- Return on invested capital
- -691.1% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- -76.3% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- -34214.6% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 4/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -28.3% Net share repurchases relative to market value.
- Shareholder yield
- -28.3% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 0.4x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Options positioningVolatility
CHRS shows volatility options pressure with a 51/100 conviction score, put-call volume ratio of 0.19, expected move of 18.1%, and Sharemaestro trend signal inactive.
Conviction51/100
Expected move18.1%
Put/call volume0.19
Insider activity17 / 3
17 acquisitions and 3 disposals in the latest 180-day insider tape.
Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.News sentiment50/100
Weighted news tone is neutral across 71 relevant articles.
12 positive · 51 neutral · 8 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings3dNext report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
Options expected move18.1%Nearest-chain priced movement where available.
52-week drawdown-46.1%Distance below the 52-week high.
13-week volatility5.1%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
6 Feb
6 Mar
3 Apr
1 May
29 May
26 Jun
31 Jul
Weeks higher12 of 2613 weeks finished lower.
Best week+17.9%Week of 17 Apr.
Worst week-24.8%Week of 13 Feb.
Latest week+0.0%Week of 31 Jul.
Shape of recent returns
Strong gains6
Modest gains6
Flat weeks1
Modest losses6
Sharp losses7
Recent vol5.1%13-week weekly-return volatility.
Base vol11.0%52-week weekly-return volatility.
Up/down split26/23Count of positive and negative weeks in the 52-week window.
Average skew9.5% / -7.4%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average-1.5%
Trend breadth52.0%
Trend52.0%active weekly trend signals
MD78.0%positive activity pressure
RS49.0%positive relative leadership
Four-week leaders
IndustryUS Biotechnology
4-week rank- / 100
Group average-4.9%
Trend breadth66.0%
Trend66.0%active weekly trend signals
MD67.0%positive activity pressure
RS63.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape24/100
Trend, activity pressure, participation, and risk combine to a 24/100 tape read.
Indicator analysis16/100Latest 12-week confirmation: trend 3/12, activity pressure 0/12, relative leadership 0/12.
Activity pressure 0.10; No reversal markers Next-Week ExpectancyNegative 40.94%Next-week expectancy is negative with a 40.94% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors28/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 93; Small Cap Core rank 82 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Options35/100CHRS shows volatility options pressure with a 51/100 conviction score, put-call volume ratio of 0.19, expected move of 18.1%, and Sharemaestro trend signal inactive.
Volatility · Volatility expansion watch · Expected move 18.1% Sentiment50/100Weighted news tone is neutral across 71 relevant articles.
BlackRock, Inc. Trims Coherus Oncology Inc (CHRS) Stake -- Shares Trade 79% Above GF Value Insiders17 / 317 acquisitions and 3 disposals in the latest 180-day insider tape.
Earnings3dNext report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 31 Jul 2026 | 1.41 USD | 0.0% | 1.66 USD | 1.75 USD | -1.19 | -15.68 | 2.4M | Off |
| 24 Jul 2026 | 1.41 USD | 0.7% | 1.65 USD | 1.77 USD | -1.13 | -14.91 | 2.0M | Off |
| 17 Jul 2026 | 1.40 USD | -9.1% | 1.65 USD | 1.79 USD | -0.95 | -16.72 | 2.8M | Off |
| 10 Jul 2026 | 1.54 USD | 6.2% | 1.65 USD | 1.81 USD | -0.90 | -11.90 | 6.8M | Off |
| 3 Jul 2026 | 1.45 USD | -3.3% | 1.64 USD | 1.83 USD | -1.10 | -15.18 | 3.2M | Off |
| 26 Jun 2026 | 1.50 USD | 1.4% | 1.64 USD | 1.85 USD | -1.14 | -11.10 | 7.2M | Off |
| 19 Jun 2026 | 1.48 USD | 5.7% | 1.63 USD | 1.87 USD | -1.20 | -15.71 | 3.8M | Off |
| 12 Jun 2026 | 1.40 USD | -3.4% | 1.62 USD | 1.89 USD | -1.10 | -17.75 | 3.3M | Off |
| 5 Jun 2026 | 1.45 USD | -8.8% | 1.61 USD | 1.90 USD | -0.88 | -12.50 | 4.5M | Off |
| 29 May 2026 | 1.59 USD | -1.2% | 1.61 USD | 1.93 USD | -0.74 | -8.01 | 4.5M | On |
| 22 May 2026 | 1.61 USD | 2.5% | 1.61 USD | 1.95 USD | -0.69 | -3.64 | 6.2M | On |
| 15 May 2026 | 1.57 USD | -10.3% | 1.61 USD | 1.96 USD | -0.68 | -4.30 | 13.1M | On |
| 8 May 2026 | 1.75 USD | -2.8% | 1.62 USD | 1.98 USD | -0.57 | 7.00 | 4.5M | On |
| 1 May 2026 | 1.80 USD | 2.9% | 1.61 USD | 2.00 USD | -0.52 | 16.56 | 3.4M | On |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.